Table 3.
Variable | (A) HEU and HUUb Combined | (B) HEU Onlyc | ||
---|---|---|---|---|
aOR (95% CI) | P Valued | aOR (95% CI) | P Value | |
HIV exposure status | ||||
HEU | 1.2 (1.0–1.5) | .04 | ---- | ---- |
HUU | Ref | |||
ARV | ---- | .04* | ||
Preconception ART | 1.7 (1.1–2.5) | .02 | ||
ZDV | 1.4 (0.9–2.0) | .11 | ||
None | 1.9 (1.1–3.1) | .01 | ||
Postconception ART | Ref | |||
Syphilis serology | ||||
Positive | 0.7 (0.4–1.2) | .22 | 0.7 (0.3–1.3) | .22 |
Negative | Ref | Ref | ||
Tuberculosis | ||||
Yes | 1.1 (0.7–1.9) | .65 | 1.1 (0.5–2.3) | .83 |
No | Ref | Ref | ||
Maternal age, years | .08* | .08* | ||
20–25 | 0.9 (0.7–1.1) | .36 | 1.5 (0.7–3.2) | .31 |
26–29 | 0.9 (0.7–1.3) | .63 | 1.5 (0.7–3.5) | .35 |
30–35 | 0.7 (0.5–0.9) | .02 | 1.0 (0.5–2.3) | .94 |
>35 | 1.0 (0.6–1.4) | .79 | 2.0 (0.9–4.6) | .11 |
<20 | Ref | Ref | ||
Parity | .20* | .08* | ||
2–3 | 0.8 (0.7–1.0) | .06 | 0.7 (0.4–0.9) | .02 |
4+ | 0.9 (0.6–1.2) | .40 | 0.7 (0.4–1.2) | .14 |
1 | Ref | Ref | ||
Maternal education | ||||
≤ grade 7 | 1.4 (1.1–1.7) | <.01 | 1.1 (0.8–1.6) | .62 |
> grade 7 | Ref | Ref | ||
ANC visits | ||||
+5 | 0.7 (0.6–0.9) | <.01 | 0.7 (0.5–1.0) | .08 |
1–5 | Ref | Ref | ||
Household socio-economic quintile | <.01* | .02* | ||
Poorest | 1.7 (1.2–2.5) | <.01 | 3.0 (1.3–6.8) | <.01 |
Second | 1.2 (0.9–1.7) | .26 | 1.7 (0.7–3.8) | .24 |
Third | 1.3 (1.0–1.8) | 1.00 | 2.6 (1.2–5.9) | .02 |
Fourth | 1.1 (0.8–1.5) | .68 | 2.1 (0.9–4.4) | .07 |
Least poor | Ref | Ref | ||
Household food insecurity | ||||
Yes | 0.8 (0.6–1.0) | .07 | 1.0 (0.6–1.5) | .82 |
No | Ref | Ref | ||
Infant race | <.01* | .41* | ||
Colored | 1.7 (1.3–2.3) | <.01 | 1.4 (0.7–2.7) | |
Other | 1.3 (0.5–3.4) | .56 | ---- | |
Black | Ref | Ref | ||
Infant gender | ||||
Male | 0.9 (0.8–1.0) | .12 | 1.1 (0.8–1.5) | .55 |
Female | Ref | Ref |
Abbreviations: ANC, antenatal care; aOR, adjusted odds ratio; ART, antiretroviral therapy; ARV, antiretroviral drug; CI, confidence interval; HEU, HIV-exposed-uninfected; HUU, HIV-unexposed; Ref, reference category; ZDV, Zidovudine.
aThe values in the models are aOR (95% CI).
bModel included 6214 HIV-exposed and -unexposed infants.
cModel included 1839 HIV-exposed-uninfected infants.
dExcept for the asterisk below, the P values in this table are t test P values. The 5% significance level was used in all analyses.
*This P value is derived from the joint hypothesis testing adjusted Wald test.